Objectives: Our objectives were to systematically assess the quality of reporting of adverse events (AEs) in publications of randomized trials of highly active antiretroviral therapy (HAART), and to examine whether reporting quality affects the effect estimates reported for AEs.
Introduction
Selection of highly active antiretroviral therapy (HAART) is currently based on the relative efficacy and toxicity of the various HAART regimens. With improving efficacy and patient life span, attention to adverse events (AEs) experienced with each regimen and the resulting quality of life has become a major determinant in selecting a HAART regimen for the individual patient. 1 Recommendations for treatment regimens are currently based on large randomized controlled trials (RCTs).
2 These trials also serve as an important platform for assessing antiretroviral drug-related AEs. Although not all AEs appear during the limited follow-up period of RCTs and some rare AEs are revealed only after longer exposure of larger populations, RCTs have the advantage of intensively following up well-characterized populations.
Guidelines on reporting of AEs in randomized trials are included in the 2001 CONSORT guidelines. 3 In a study assessing completeness of safety reporting in 192 randomized controlled trials, inadequate and incomplete AE reporting were found in all seven medical areas examined, including HIV. 4 Consequently, an extension of the CONSORT statement was published addressing AEs specifically. 5 Moreover, in the area of HIV, Carr 6 pointed out weaknesses in the monitoring, analysis and reporting of AEs in trials assessing antiretroviral therapy, and formulated a set of recommendations for improvement, addressing the special problems of these trials.
We systematically assessed the quality of reporting of AEs in publications of randomized trials of HAART. We assessed trials comparing triple drug regimens since these represent the standard of practice for HIV-infected patients. We limited our analysis to trials assessing treatment-naive patients, who have the option of several different potent treatment combinations and among whom the AE profile has a major bearing on treatment decisions. We sought to examine whether reporting quality affects the effect estimates reported for AEs. Secondarily, we assessed the effect of sponsorship on the quality and characteristics of AE reporting.
Methods

Data sources and searches
We searched the PubMed, Cochrane library and EMBASE electronic databases and references of included studies up to December 2008. In addition, we examined all references of included trials. We combined search phrase I and search phrase II of the search below. For PubMed, this search was also combined with the Cochrane filter for RCTs. 
Study selection
We included RCTs irrespective of language or date of publication that enrolled treatment-naive HIV-infected patients aged 16 years. We included only trials that compared combination therapy regimens of three or more drugs in both trial arms, with follow-up data of 48 weeks. We looked for AE results reporting in secondary publications for the same trials. We excluded trials that were not published as full text articles, since we did not expect full reporting of AEs in abstracts.
Data extraction and quality assessment
One reviewer performed the search and inspected the abstract of each reference identified (M. Y. C.). When relevant articles were identified, the full article was obtained and inspected independently by two reviewers who applied inclusion criteria and independently extracted the data (M. Y. C. and B. S. G.). Differences in the data extracted were resolved by discussing them with a third reviewer (M. P.).
We assessed quality measures addressed by the CONSORT guidelines for AEs 5 and adjusted to the design of HAART trials. 6 For each item below we scored whether present or absent, and recorded the data when presented. Definitions and rules: † AE and severity grading score definitions (or reference to standardized definitions); † mode of data collection: active/ passive, questionnaires, interviews, open-ended versus structured questionnaires; † timing and frequency of AE assessments; † rules for discontinuation.
Attribution and selective reporting: † reporting of AEs by intention to treat; † attribution of AEs to the trial drugs; † the use of a severity threshold (e.g. reporting of AEs only above a certain severity grade); † The use of an occurrence threshold (e.g. reporting of AEs occurring only above a certain percentage of patients).
AE-related outcomes: † treatment discontinuations or modifications due to AEs and details on the reasons for discontinuation; † withdrawals resulting from AEs; † deaths due to AEs.
In addition, we collected data on the rates of AEs (including any clinical and laboratory AEs and specific AEs), whether drug switches were allowed by protocol and whether the number of patients switching treatment per protocol was reported; study years and year of publication, and sponsorship (whether industry or not). We extracted the source of funding from the text, authors' affiliations, acknowledgement and statement of source of support.
Data synthesis and analysis
We compared the methods of AE reporting in studies sponsored solely by industry and studies planned and sponsored by other sources, termed thereafter non-profit organizations (government grants, academic grants, etc.). Since the extension of the CONSORT statement to AEs was published in 2004 5 and since it takes time from the writing of an article until its publication, we compared AE reporting in studies published up to 2005 and those published from 2006 onwards. To assess whether the methods of AE reporting affected the differences shown between the experimental and the control arms, we calculated the relative risks (RRs) for AEs with 95% confidence intervals (CIs) in individual trials and compiled these using a fixed effect model, unless significant heterogeneity was present (P,0.1) where the random effects model was used. Only trials that had clearly defined one arm as experimental and the other as control were included in this analysis and the classification of experimental versus control of the original trial was used. AEs requiring discontinuation were selected for this analysis as the most objective outcome reported and since discontinuations were reported by patient (rather than by episode). We compared different reporting methods using subgroup analysis.
The effect of continuous variables (e.g. year of publication) on RRs was assessed through fixed-effect meta-regression. Analyses were performed using Comprehensive Meta-Analysis version 2.2.
Results
Forty-nine RCTs, including 19 882 HIV treatment-naive patients, were found eligible for our study (Figure 1 ). The median number of patients per trial was 298 . Thirty-one trials were sponsored by industry and 18 by non-profit organizations. Although we did not restrict our search in time, all studies included were published from the year 2000 onwards. Studies published before the year 2000 had shorter follow-up, Systematic review included nucleoside reverse transcriptase inhibitor (NRTI)-experienced patients or compared dual therapy. Trials included and the methods used for reporting AEs in these trials are detailed in Table 1 .
AE definitions and rules
Definitions of the AEs collected, with reference to standardized and validated definitions (WHO or NIAID 8 ), were given in 33 of the trials (67%). Information about the collection mode was scarce. The majority of the trials (40 trials; 82%) stated that AEs were 'recorded' or 'monitored' without providing information on whether AEs were collected by interview, open-ended questions or structured questionnaire. Seven trials did not refer at all to the methods of AE collection. One trial reported that the development of lipodystrophy was assessed by a questionnaire, but did not specify the method of collection of all other AEs. 9 Only one study provided information on the way AEs were collected. 10 The timing and frequency of study visits were defined in all trials, but none of the trials specified whether specific AEs were more common early or late after treatment initiation. Discontinuation rules were defined in 12 trials (24%).
Attribution and selective reporting
All harms, whether considered related or unrelated to the study drugs, were reported in 12 trials (24%). Twenty-six trials reported only AEs attributed to therapy, and in one study both attributable harms and all harms were reported. 11 In 10 trials it was not clear from the text or from the figure legends whether AEs reported were attributed to therapy. In 17 of the 27 trials that reported on AEs attributed to therapy, there was no reference to the attribution procedure (how, who, etc.).
AE reporting was mostly selective, either by the AE severity levels or by the occurrence threshold selected for presentation. Most trials based their grading on the National Institute of Allergy and Infectious Diseases (NIAID) severity grading scale. Clinical AEs were presented in the following way: 16 trials presented all severity grades (1 -4), 19 trials presented only grades 2-4, 10 trials grades 3-4, 1 trial grade 4 and 3 trials presented only AEs that led to discontinuation. Of the 35 trials that included mild and moderate AEs in their report (grades 1 -2), severe and serious AEs (3 -4) were presented separately in only 10 trials. In the presentation of laboratory AEs, 7 trials presented AEs with a severity grade of 1 -4, 4 trials used grades 2 -4, 35 trials grades 3-4 and 3 trials reported only AEs that led to discontinuation. Moreover, one trial reported the aggregate number of all grade 3 and 4 AEs in both treatment arms, one reported information on a single AE of interest, one trial provided only the aggregate number of grade 4 AEs and one trial provided only the aggregate number of AEs leading to discontinuation.
Thirty-three trials (67%) reported AEs only above an occurrence threshold. Seven trials reported only AEs occurring in above 2% of patients, four above 3%, nine above 5%, three above 10%, two above 15% and one trial reported only AEs occurring in .20% of the patients. 12 One trial reported on AEs occurring in .10% of the patients only if there was a statistically significant difference between the study arms. 13 Moreover, two trials reported 'the most frequent AEs' and three reported 'selected AEs', with no reference as to the selection mode. Only 16 trials reported AEs with no pre-selection.
AE-related outcomes
Most of the trials (46 of 49) reported on the number of patients who discontinued the study due to AEs, but only half (23) provided the types of AE responsible for the discontinuation. In 24 of the trials, a switch to other drugs was allowed during the study by protocol in cases of toxicity; the number of switches was mentioned in only 12 of these (50%). In 10 of the 12, the number of switches was given per study arm.
Effect of sponsorship and year of publication on AE reporting
A bigger proportion of trials sponsored by industry described mild and moderate AEs compared with trials sponsored by non-profit organizations, who reported mainly serious AEs. However, industry-sponsored trials presented in the vast majority of cases (97%) only AEs appearing above a certain threshold in the study population (Table 2) . Moreover, less information was given in trials sponsored by industry on the reasons for study discontinuation due to AEs (35% versus 67% for non-profit organizations).
Thirty-three of the trials were published before the end of 2005 and 16 were published between 2006 and 2008. Starting in 2006 more studies reported AE definitions (P ¼ 0.035), more studies reported the number of switches in study drugs, when those switches were allowed by protocol (P ¼ 0.007), but fewer studies published their discontinuation rules (P ¼ 0.037). In all other parameters no change was observed over the years.
Effects of reporting quality methods on the estimates of effect for AEs
We calculated the RRs for discontinuations due to AEs in each trial and compared pooled results given different study characteristics (Table 3 ). There was no significant heterogeneity in these comparisons. Reporting of AEs by intention to treat rather Systematic review The experimental regimen is highlighted in bold in trials comparing an experimental regimen with control. QD, once a day; BID, twice a day; ZDV, zidovudine; 3TC, lamivudine; d4T, stavudine; ddI, didanosine; TNF, tenofovir; ABC, abacavir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir; LOP, lopinavir; AMP, amprenavir; FPV, fosamprenavir; ATZ, atazanavir; RAL, raltegravir; DRN, darunavir; /r, ritonavir; X, drug not predefined (at the discretion of the treating physician). a AG, allocation generation (how randomization was generated: computer, tables, sequence of appearance). 
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than on-treatment was significantly associated with a benefit for the experimental arm. AE definitions were reported more in trials showing a benefit for the intervention with regard to treatment discontinuations. There was no association between the year of publication and the RRs for discontinuations due to AEs.
Discussion
The field of HIV therapy has undergone a major change in the last two decades, from monotherapy given to AIDS patients in the late stages of their disease, to potent triple therapy given to asymptomatic patients. With the acceptance of lifelong therapy Pooled relative risks (RRs) for discontinuations due to AEs per patient (fixed effect model) are reported with 95% confidence interval (95% CI). Only studies in which an experimental arm was compared with a control arm were included. RRs ,1 favour the experimental group (less discontinuations due to AEs reported in the experimental group). The statistical significance (unadjusted P) for the difference between RRs obtained from trials with and without the stated variables is given. Detailed AEs that led to discontinuation (%) 11 (35) 12 (67) Systematic review came an understanding of the need for near-perfect adherence in order to avoid resistance, and to maintain treatment potency. This adherence is possible only with drugs that would not disrupt the patient's daily routine and would allow them to live as normal a life as possible; hence the importance of the AE profile of different drugs. We systematically reviewed the methods of reporting of AEs in RCTs assessing triple-therapy HAART for treatment-naive HIV-infected patients.
We found large variability and a lack of standardization in the reporting of AEs in these trials. Reporting was highly selective regarding severity grade, an occurrence threshold and attribution to study drugs. The severity of AEs reported ranged from all mild AEs to only those that led to discontinuation. The minimal frequency of occurrence used for reporting AEs seemed arbitrary (or chosen), ranging from none to AEs appearing in .20% of the study population. The CONSORT statement recommends reporting of severe AEs separately from mild AEs and to avoid reporting AEs only above a certain occurrence threshold. 5 The number of patients treated with a drug following its approval is over 1000 times its exposure in the trials before approval.
14 Thus, even severe AEs occurring in one patient during the trial can have serious ramifications later on. To report only those AEs that appeared in .5% or 10% of the study population is to disregard valuable gathered information critical to physicians and patients. On the other hand, by choosing to report only patients with grade 3-4 AEs we can miss common mild to moderate AEs, which although not life threatening can be disrupting enough to decrease longterm compliance.
Only one of the published trials gave specific information on how clinical AEs were collected. The way AEs are collected has a major influence on the frequency found. Passive surveillance will yield fewer AEs than active surveillance, and structured questionnaires might remind patients of specific AEs that were overlooked, forgotten or deemed irrelevant by the patient. 15, 16 A sentence such as 'Patients were monitored for AEs', which appeared in many publications, supposedly relates to AE collection, but is uninformative. We showed that differences in the methods of reporting AEs may affect the results reported for AEs or that those results dictate the quality of reporting methods. Reporting on AEs by intention to treat rather than on-treatment and reporting AE definitions were associated with a benefit for the trial's defined experimental arm with regard to discontinuations of treatment due to AEs. We observed no significant improvement in the quality of AE reporting over the last 3 years.
Non-profit-sponsored trials tended to report only serious AEs, without an occurrence threshold. Trials sponsored by industry usually reported all or grade 2-4 AEs, above an arbitrary threshold. This tends to overrepresent common and mild AEs, while the serious AEs are filtered by the occurrence threshold (Table 2) . Industry sponsorship has been associated previously with pro-industry study design, with regard to the selection of the control group or drug dosing and pro-industry conclusions. 17 We show that AE reporting might also be affected, although some diversity might be expected due to the inherent differences between industry-sponsored trials assessing new drugs and non-profit-sponsored trials assessing more commonly a treatment policy, drug class dosing, treatment schedule, etc. Standardization of AE reporting methods can overcome possible bias with regard to AE reporting.
A limitation of our study was the sole reliance on published data. We did not try to obtain further data on AE collection methods or AE results directly from the authors or the sponsors. The focus of our study was to assess reporting methods in the published sources, since these are the data that are available to clinicians, patients and guideline developers selecting HAART regimens. Our sponsorship attribution was based on that declared in the publications; we did not try to confirm published sponsorship statements. Finally, the variables assessed in our analysis of the effects of AE reporting methods on results are not independent, thus we report on a cluster of factors that affected the results shown for AEs rather than individual variables.
Given the importance of antiretroviral drug-related AEs and their special attributes, particular standards for the collection, analysis and reporting of AEs in HAART trials should be established. Several implications can be drawn from our observations and previously published recommendations. 5, 6 An HIV expert panel should define HAART-unique AEs, whose reporting will be mandatory in randomized trials, and specify the recommended surveillance methods and severity grading. For example, lipodystrophy is a unique and emerging AE; it can be assessed clinically relying on physician's assessment, patient's self-assessment or using dual-energy X-ray absorptiometry (DEXA) and each method will yield significantly different occurrence rates.
All (or .1%) AEs should be collected, with no occurrence or severity thresholds. AE severity, using standardized definitions, time of occurrence after study initiation and persistence should be recorded. Data collection can be improved with the addition of a checklist questionnaire to the patient as opposed to open-ended questions, 15 although active reporting should also be encouraged to identify previously unrecognized AEs. 6 The final publication should include AE definitions, collection methods and discontinuation rules. All AEs should be reported by severity grading and unlike efficacy data, for the on-treatment population rather than by intention to treat, since we show that this might affect the results reported. Carr 6 also recommends reporting virus-related outcomes on the adherent population to minimize bias due to AE-related study drug discontinuation on virus-related outcomes. Any AE, drug-related AE and all discontinuations due to an AE, including those allowed by protocol, should be reported. The treating physician cannot be expected to access sponsor data or data submitted to licensing authorities for this much needed information. For space considerations, journals might consider including routinely a link to the study protocol, requiring a full specification of AE collection methods, and publish all results related to AEs as supplementary online material.
The currently observed variability precludes the possibility of comparing or compiling AEs reported in different HAART trials and with post-marketing observational studies. Thus, the ability to report AEs in systematic reviews is impaired. 18 Authors and editors should ensure that reporting of AEs in HAART trials follows the CONSORT guidelines for reporting on harms in randomized trials. 5 Future guidelines should address more specifically AE reporting in HAART trials.
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